Q-omics provides the consensus-scored FUNDC2P2 profile across patient tissues and cancer cell-line models. FUNDC2P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, FUNDC2P2 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, FUNDC2P2 RNA expression shows 6,183 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, COAD, and STAD as cancer lineages where FUNDC2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUNDC2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUNDC2P2 survival associations across molecular data types. FUNDC2P2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUNDC2P2 RNA expression–survival associations across cancer types. High FUNDC2P2 expression shows unfavorable associations in CHOL, KICH and STAD, but favorable associations in MESO, CESC and BLCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for FUNDC2P2 RNA expression.
This table summarizes FUNDC2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FUNDC2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUNDC2P2 shows lower tumor expression in KIRC and CHOL and higher tumor expression in COAD, LUAD, LIHC and THCA. The COAD box plot shows higher FUNDC2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.176, t-test p < 0.001).
This table shows molecular features associated with FUNDC2P2 in patient tissues and cancer cell lines. In patient samples, FUNDC2P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FUNDC2P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
